HR outsourcing provider Insperity (NYSE: NSP) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 3.3% year on year to $1.66 billion. Its non-GAAP profit of $0.26 per share was 36.3% below analysts’ consensus estimates.

Is now the time to buy NSP? Find out in our full research report (it’s free).

StockStory’s Take

Insperity’s second quarter was marked by a significant market reaction to its results, as investors focused on the company’s declining operating margins and higher-than-expected benefits costs. Management cited a 9.6% year-over-year increase in benefits expenses, driven by higher utilization of specialty drugs and an uptick in large medical claims, particularly for cancer and heart-related conditions. CEO Paul Sarvadi acknowledged the company’s “resilience and agility” in maintaining client retention and sales efficiency in a challenging economic environment, but also described the margin pressure as a direct result of continued healthcare cost escalation and unfavorable claims development.

Looking ahead, Insperity’s updated guidance reflects management’s expectation that elevated benefits costs will persist through the remainder of the year, prompting a cautious outlook for profitability. The company is prioritizing a three-pronged response: implementing higher pricing for new and renewing clients, introducing changes to health plan designs, and negotiating key contract terms with UnitedHealthcare. CFO Jim Allison emphasized that most of the margin recovery will rely on pricing actions, while Sarvadi noted, “We remain confident in our outlook for accelerated growth and improved profitability in 2026,” though he cautioned that improvement will depend on successful execution of these cost-control measures.

Key Insights from Management’s Remarks

Management attributed the challenging quarter to persistent healthcare cost pressures, offset by efficiency gains in sales and the launch of new HR solutions.

• Benefits cost escalation: Ongoing increases in employee health benefit costs, particularly from specialty pharmacy drugs and large medical claims, continued to pressure gross margins. Management pointed to a $12 million overage above forecast, with specialty drug utilization and higher per-prescription costs as key drivers.
• Sales efficiency improvement: Despite an 11% reduction in the Business Performance Advisor (BPA) headcount, Insperity achieved a 13% increase in sales efficiency, demonstrating effectiveness in client acquisition with a leaner, more experienced salesforce.
• Retention and client base stability: Client retention remained high at 99% per month, indicating strong client satisfaction and continued reliance on Insperity’s HR services despite the challenging environment.
• HR solutions portfolio update: The company rebranded its flagship offerings (HR 360, HR Core, HRScale) and accelerated its partnership with Workday, including a target launch for HRScale beta clients early next year. This is expected to expand Insperity’s addressable market, especially among mid-market organizations.
• Operating expense discipline: Operating expenses declined 3% year-over-year, driven by reductions in travel, professional fees, and G&A costs, even as investments continued in the Workday partnership and marketing initiatives.

Drivers of Future Performance

Insperity expects future performance to hinge on its ability to manage healthcare cost trends, execute pricing actions, and capitalize on new product launches.

• Pricing and plan design changes: Management is implementing higher pricing targets for both new and renewing clients, alongside plan design adjustments effective January 2026. These measures are intended to mitigate rising benefits costs and restore gross profit margins.
• Workday partnership and HRScale launch: The upcoming launch of Insperity HRScale, a joint product with Workday, is positioned to broaden the company’s reach into larger mid-market clients and support higher-margin, scalable growth. Management highlighted the potential for premium pricing and improved sales efficiency as the beta program expands in 2026.
• Expense management and operational leverage: Continued focus on controlling operating expenses and leveraging technology, including AI tools for HR professionals, is expected to contribute to improved profitability, although initial onboarding and product rollout costs may weigh on near-term results.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team will monitor (1) execution and client adoption of the HRScale beta launch and subsequent expansion, (2) measurable progress in offsetting healthcare cost inflation through pricing and benefit design, and (3) continued improvements in sales efficiency and client retention. Sustained operating expense discipline and further integration of technology investments will also be key indicators of Insperity’s ability to deliver on its long-term profitability targets.

Insperity currently trades at $50.38, down from $59.61 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.